ArticleEMBO reports2017
GRWD1 negatively regulates p53 via the RPL11-MDM2 pathway and promotes tumorigenesis.
Article in EMBO reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 74 citations in OpenAlex.
- The Nucleolus in Human Disease: Ribosome Biogenesis, Nucleolar Surveillance, and Therapeutic Opportunities.Biomolecules · 2026Review
- GRWD1 as a Novel Signature and It Down Regulates IFN in Skin Aging.Cell biochemistry and function · 2026Article
- GRWD1 enhances HSV-1 replication by facilitating nuclear egress.Microbiology spectrum · 2026Article
- Diagnostic and therapeutic potential of exosomal circRNAs in cancer: decoding the circular code toward precision medicine.Cancer cell international · 2025Review
- GRWD1 Drives Melanoma Growth Through NF-κB Signaling Pathway.Dermatology practical & conceptual · 2025Article
- IL6/STAT3 induced GRWD1 mediates aerobic glycolysis via P53/GLUT1 signal axis in colon carcinoma.Scientific reports · 2025Article
- Modulation of Gene Expression by Substrate Stiffness via Ubiquitination of Histone H2B by Ubiquitin-Conjugating Enzyme E2A/B.ACS omega · 2025Article
- The Genetic Architecture of Congenital Diarrhea and Enteropathy.The New England journal of medicine · 2025Article
- Identification of Progression-Associated Biomarkers in Lung Cancer Based on the Integrated Analysis of RNA Sequencing Data From Platelets and Tumor Tissues.International journal of genomics · 2025Article
- GRWD1 Over-Expression Promotes Gastric Cancer Progression by Activating Notch Signaling Pathway via Up-Regulation of ADAM17.Digestive diseases and sciences · 2024Article
- Structure of nascent 5S RNPs at the crossroad between ribosome assembly and MDM2-p53 pathways.Nature structural & molecular biology · 2023Article
- ZNF330/NOA36 interacts with HSPA1 and HSPA8 and modulates cell cycle and proliferation in response to heat shock in HEK293 cells.Biology direct · 2023Article
- GRWD1 affects the proliferation, apoptosis, invasion and migration of triple negative breast cancer through the Notch signaling pathway.Experimental and therapeutic medicine · 2022Article
- Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.Nature communications · 2022Article
- RPL15 promotes hepatocellular carcinoma progression via regulation of RPs-MDM2-p53 signaling pathway.Cancer cell international · 2022Article
- Article
- Localization and Functional Roles of Components of the Translation Apparatus in the Eukaryotic Cell Nucleus.Cells · 2021Review
- Comprehensive Analysis of Glutamate-Rich WD Repeat-Containing Protein 1 and Its Potential Clinical Significance for Pancancer.BioMed research international · 2021Article
- Clinical Significance and Oncogenic Activity of GRWD1 Overexpression in the Development of Colon Carcinoma.OncoTargets and therapy · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ribosomal protein L11 (RPL11) binds and inhibits the MDM2 ubiquitin ligase, thereby promoting p53 stability. Thus, RPL11 acts as a tumor suppressor. Here, we show that GRWD1 (glutamate-rich WD40 repeat containing 1) physically and functionally interacts with RPL11. GRWD1 is localized to nucleoli and is released into the nucleoplasm upon nucleolar stress. Silencing of GRWD1 increases p53 induction by nucleolar stress, whereas overexpression of GRWD1 reduces p53 induction. Furthermore, GRWD1 overexpression competitively inhibits the RPL11-MDM2 interaction and alleviates RPL11-mediated suppression of MDM2 ubiquitin ligase activity toward p53. These effects are mediated by the N-terminal region of GRWD1, including the acidic domain. Finally, we show that GRWD1 overexpression in combination with HPV16 E7 and activated KRAS confers anchorage-independent growth and tumorigenic capacity on normal human fibroblasts. Consistent with this, GRWD1 overexpression is associated with poor prognosis in cancer patients. Taken together, our results suggest that GRWD1 is a novel negative regulator of p53 and a potential oncogene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.